Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.

[1]  K. Döhner,et al.  Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. , 2017, Leukemia research.

[2]  S. Verstovsek,et al.  Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl , 2016 .

[3]  Haiching Ma,et al.  Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor , 2016, Journal of experimental pharmacology.

[4]  H. Kantarjian,et al.  Clinical features and outcome of patients with poor-prognosis myelofibrosis based on platelet count <50 x 109/L: A single-center experience in 1100 myelofibrosis patients. , 2016 .

[5]  R. Laborde,et al.  A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. , 2015, The New England journal of medicine.

[6]  L. To,et al.  Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. , 2015, Blood.

[7]  S. Verstovsek,et al.  Novel therapies for myelofibrosis , 2015, Leukemia & lymphoma.

[8]  R. Mesa,et al.  Therapy for myeloproliferative neoplasms: when, which agent, and how? , 2014, Hematology. American Society of Hematology. Education Program.

[9]  F. Cervantes.  How I treat myelofibrosis. , 2014, Blood.

[10]  D. Starczynowski,et al.  IRAK signalling in cancer , 2014, British Journal of Cancer.

[11]  E. Hatzimichael,et al.  Profile of pacritinib and its potential in the treatment of hematologic disorders , 2014, Journal of blood medicine.

[12]  A Caflisch,et al.  Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348) , 2014, Leukemia.

[13]  H. Kantarjian,et al.  Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes , 2013, OncoTargets and therapy.

[14]  M. Cazzola,et al.  Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence , 2013 .

[15]  H. Kantarjian,et al.  Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts , 2013, Journal of Hematology & Oncology.

[16]  Francisco Cervantes,et al.  Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. , 2013, Blood.

[17]  J. Dipersio,et al.  The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis , 2013, British journal of haematology.

[18]  R. Laborde,et al.  Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis , 2013, Leukemia.

[19]  Delong Liu,et al.  Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application , 2013, Biomarker Research.

[20]  Jason Gotlib,et al.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.

[21]  Francisco Cervantes,et al.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.

[22]  A. Tefferi.  How I treat myelofibrosis. , 2011, Blood.

[23]  F. Passamonti,et al.  DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Tefferi,et al.  CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients , 2009, Leukemia.

[25]  E. Stanley,et al.  Colony-stimulating factor-1 in immunity and inflammation. , 2006, Current opinion in immunology.

[26]  G. Stark,et al.  A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin‐6. , 1995, The EMBO journal.

[27]  A. Caflisch,et al.  Specificity and Mechanism-of-action of the Jak2 Tyrosine Kinase Inhibitors Ruxolitinib and Sar302503 (tg101348) , 2022 .

[28]  A. Tefferi,et al.  One thousand patients with primary myelofibrosis: the mayo clinic experience. , 2012, Mayo Clinic proceedings.

[29]  T. Barbui,et al.  What are RBC-transfusion-dependence and -independence? , 2011, Leukemia research.

[30]  J. Sloan,et al.  The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) , 2007, Cancer.